AU2004317548A1 - Use of EMMPRIN antagonists for the treatment of diseases associated with excessive angiogenesis - Google Patents
Use of EMMPRIN antagonists for the treatment of diseases associated with excessive angiogenesis Download PDFInfo
- Publication number
- AU2004317548A1 AU2004317548A1 AU2004317548A AU2004317548A AU2004317548A1 AU 2004317548 A1 AU2004317548 A1 AU 2004317548A1 AU 2004317548 A AU2004317548 A AU 2004317548A AU 2004317548 A AU2004317548 A AU 2004317548A AU 2004317548 A1 AU2004317548 A1 AU 2004317548A1
- Authority
- AU
- Australia
- Prior art keywords
- emmprin
- angiogenesis
- cells
- mmp
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2004/009151 WO2005092381A1 (fr) | 2004-03-25 | 2004-03-25 | Utilisation d'antagonistes de l'inducteur de metalloproteinase dans la matrice extracellulaire pour le traitement de maladies associees a un angiogenese excessive |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2004317548A1 true AU2004317548A1 (en) | 2005-10-06 |
Family
ID=35055994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004317548A Abandoned AU2004317548A1 (en) | 2004-03-25 | 2004-03-25 | Use of EMMPRIN antagonists for the treatment of diseases associated with excessive angiogenesis |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1732599A4 (fr) |
JP (1) | JP2007530538A (fr) |
CN (1) | CN1960753A (fr) |
AU (1) | AU2004317548A1 (fr) |
CA (1) | CA2560903A1 (fr) |
WO (1) | WO2005092381A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4911950B2 (ja) * | 2005-11-07 | 2012-04-04 | 晃 伊東 | Mmp−1の部分ペプチドを用いた癌浸潤・転移阻害薬 |
CN102316898A (zh) * | 2008-09-29 | 2012-01-11 | 森托科尔奥索生物科技公司 | 抗cd147抗体、方法和用途 |
US10709702B2 (en) * | 2015-10-08 | 2020-07-14 | Amd Therapeutics Llc | Treatment of skin disorders by topical administration of VEGF inhibitors |
CN108101993B (zh) * | 2018-01-02 | 2019-10-15 | 北京大学 | 一种抗cd147纳米抗体、其生产方法及应用 |
WO2019157224A1 (fr) | 2018-02-07 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Procédés et compositions pour l'administration de protéines thérapeutiques |
WO2021215836A1 (fr) * | 2020-04-22 | 2021-10-28 | 신풍제약주식회사 | Composition pharmaceutique destinée au traitement ou à la prévention de maladies oculaires comprenant un dérivé de verbénone |
CN114525252B (zh) * | 2022-03-10 | 2023-12-01 | 广州源井生物科技有限公司 | 一种提高mda-mb-231单细胞克隆形成率的单克隆增强培养基与培养方法及其应用 |
WO2023174147A1 (fr) * | 2022-03-18 | 2023-09-21 | Alphelix Biotech Co., Ltd. | Anticorps se liant spécifiquement à cd147 et leurs utilisations |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2978899A (en) * | 1998-03-03 | 1999-09-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
WO2002013763A2 (fr) * | 2000-08-10 | 2002-02-21 | The Picower Institute For Medical Research | Traitement de l'infection par vih-1 et de maladies inflammatoires au moyen d'antagonistes du recepteur de la cyclophiline |
EP1390497A2 (fr) * | 2001-05-25 | 2004-02-25 | Genset | Adnc et proteines humaines, ainsi que leurs utilisations |
DE60230269D1 (de) * | 2001-05-25 | 2009-01-22 | Zhinan Chen | HAb18G/CD147, DESSEN ANTAGONIST UND ANWENDUNG |
-
2004
- 2004-03-25 JP JP2007504930A patent/JP2007530538A/ja not_active Withdrawn
- 2004-03-25 EP EP04821758A patent/EP1732599A4/fr not_active Withdrawn
- 2004-03-25 CA CA002560903A patent/CA2560903A1/fr not_active Abandoned
- 2004-03-25 WO PCT/US2004/009151 patent/WO2005092381A1/fr active Application Filing
- 2004-03-25 CN CNA200480043088XA patent/CN1960753A/zh active Pending
- 2004-03-25 AU AU2004317548A patent/AU2004317548A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005092381A1 (fr) | 2005-10-06 |
EP1732599A1 (fr) | 2006-12-20 |
CN1960753A (zh) | 2007-05-09 |
CA2560903A1 (fr) | 2005-10-06 |
JP2007530538A (ja) | 2007-11-01 |
EP1732599A4 (fr) | 2008-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1829740B (zh) | 结缔组织生长因子抗体 | |
RU2346701C2 (ru) | ХИМЕРНЫЕ И ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ ИНТЕГРИНА α5β1, КОТОРЫЕ МОДУЛИРУЮТ АНГИОГЕНЕЗ | |
AU2007237096C1 (en) | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof | |
JP7107914B2 (ja) | VE-PTP(HPTP-β)を標的化するヒト化モノクローナル抗体 | |
US20090028862A1 (en) | Emmprin antagonists and uses thereof | |
JP5829260B2 (ja) | 抗エンドグリン抗体及び抗vegf剤を用いる癌の併用療法 | |
JP2019059753A (ja) | 抗体製剤及びその使用 | |
JP2002534359A (ja) | 血管内皮細胞増殖因子アンタゴニストとその用途 | |
WO2004045507A2 (fr) | Utilisations anti-angiogeniques d'antagonistes de il-6 | |
KR20150018533A (ko) | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 | |
US20090017011A1 (en) | Modulation of vegf-c/vegfr-3 interactions in the treatment of rheumatoid arthritis | |
TW201720843A (zh) | 用於治療纖維化及/或纖維化病症之抗-αV整合素抗體 | |
US20110110932A1 (en) | Combination treatment for ocular diseases | |
AU2004317548A1 (en) | Use of EMMPRIN antagonists for the treatment of diseases associated with excessive angiogenesis | |
AU783019B2 (en) | Novel method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and beta1 integrins | |
US20050214302A1 (en) | Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis | |
US20050100550A1 (en) | Anti-angiogenic uses of IL-6 antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |